Exact Sciences (NASDAQ:EXAS – Get Rating) and DermTech (NASDAQ:DMTK – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.
Valuation and Earnings
This table compares Exact Sciences and DermTech's gross revenue, earnings per share (EPS) and valuation.
Get
Exact Sciences alerts:
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Exact Sciences | $1.77 billion | 3.70 | -$595.63 million | ($4.23) | -8.73 |
| DermTech | $11.84 million | 14.77 | -$78.33 million | ($3.56) | -1.63 |
DermTech has lower revenue, but higher earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than DermTech, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Exact Sciences and DermTech's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Exact Sciences | -37.90% | -22.07% | -11.19% |
| DermTech | -748.29% | -49.02% | -43.48% |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Exact Sciences and DermTech, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Exact Sciences | 0 | 2 | 10 | 0 | 2.83 |
| DermTech | 0 | 1 | 3 | 0 | 2.75 |
Exact Sciences presently has a consensus target price of $69.14, suggesting a potential upside of 87.33%. DermTech has a consensus target price of $19.33, suggesting a potential upside of 232.19%. Given DermTech's higher possible upside, analysts clearly believe DermTech is more favorable than Exact Sciences.
Volatility & Risk
Exact Sciences has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, DermTech has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.
Institutional and Insider Ownership
94.5% of Exact Sciences shares are held by institutional investors. Comparatively, 75.1% of DermTech shares are held by institutional investors. 1.3% of Exact Sciences shares are held by company insiders. Comparatively, 3.6% of DermTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
About Exact Sciences
(Get Rating)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
About DermTech
(Get Rating)
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
